Kodak’s Continenza Cagey About Pharma Future
Company Says It Is Cooperating With Insider Trading Investigations
Executive Summary
Kodak CEO Jim Continenza is revealing nothing about ongoing investigations, which leave Kodak’s plans to venture into pharmaceuticals – along with a $765m federal loan – uncertain.